Carcinomas neuroendocrinos : Revisión de la literatura y presentación de 20 casos

Robinson Rodríguez; Susana González; Matilde Gericke

doi:10.35954/SM1998.20.1.6

Autores/as

Robinson Rodríguez Servicio de Oncología Clínica del Hospital de Clínicas https://orcid.org/0000-0001-8495-8934
Susana González Servicio de Oncología Clínica del Hospital de Clínicas
Matilde Gericke Servicio de Oncología Clínica del Hospital de Clínicas

DOI:

https://doi.org/10.35954/SM1998.20.1.6

Palabras clave:

Carcinomas neuroendócrinos, carcinoides, oat cell no de pulmón.

Resumen

Las neoplasias neuroendócrinas se originan en el amplio y disperso sistema neuroendócrino derivado de la cresta neural. Se clasifican en grupo 1 o epiteliales (carcinomas neuroendócrinos) y grupo 2 o neurales. Se revisa la literatura y se presenta la evolución y el tratamiento de 20 casos de carcinomas neuroendócrinos. Los extremos de la biología y comportamiento clínico lo integran el carcinoide típico de apéndice y pulmón de comportamiento indolente y el carcinoma a células pequeñas (oat cell) muy agresivo.
Correspondieron al sexo Femenino: 12 y al Masculino: 8. Edad media: 51 años (14 a 72). Tres presentaron síndrome carcinoide (diarrea 2, flushing y diarrea 1). Un paciente con carcinoma neuroendócrino (CNE) de ovario presentó síndrome de Cushing. Cinco presentaron secreción anormal de 5 HIAA en orina. En tubo digestivo se localizaron 8 carcinoides, 2 CNE, 4 oat cell de esófago. Los otros casos fueron 1 carcinoide de pulmón, 1 carcinoide mucosecretante de mama, 1 CNE de ovario, 2 carcinoides y un oat cell de primitivo desconocido.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Citas

(1) FEYRTER F. Carcinoid and carcinoma. Ergebn Allg Pathol 1934; 29: 305-489.

(2) PEARSE AGE. The cytochemestry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, and physiologic of the concept. J HistocCytochem 1969; 17: 303.

(3) WICK MARK K. Neuroendocrine Neoplasia: An overvierw of current concept and terminology. American Society of Clinical Oncology, 30th. Annual Meeting. Educational Book 1994, 246-248.

(4) HALLER DG. Carcinoid and islet cell tumors of the gastrointestinal tract. Chapter 33, p. 449-460. En Gastrointestinal Oncology. Ahlgren JD, Mac Donald JS. JB Lippincott Company. Philadelphia. USA 1992.

(5) MOERTEL CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 1503-1522.

(6) Oberg K, Erikson B. Medical treatment of Neuroendocrine gut and pancreatic tumors. Acta Oncol 1989; 28: 425-431.

(7) BRENNAN F, MAC DONALD JS. Carcinoid tumors. Chapter 35. En Cancer. Principios y Práctica de Oncología. De Vitta V, Hellman S. Barcelona. Salvat 1987.

(8) LARSON C, SHOGSEID B, OBERG K. Men-1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.

(9) SOGA J, TAZAWA K. Pathology analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971; 28: 990-998.

(10) CARNEY JA, GO VLW, FAIRBANKS VF, MOORE SB. The syndrome of gastric argyrophill carcinoid tumors and non antral gastric atrophy. Ann Intern Med 1983; 99: 761-766.

(11) BORCH K, RENVALL H, LIEDBERG G. Gastric endocrine cell hiperplasia and carcinoid tumors in Pernicious Anemia. Gastroenterol 1985; 88: 638- 648.

(12) ITSUNO M, WATANABE H, IWAFUCHI M, ITO S. Multiple carcinoids and endocrine cell micronets in type A gastritis. Cancer 1989; 63: 881-890.

(13) BORDI C, YU JY, BAGGI MT, DAVOLI C, PILATO FP. Gastric carcinoids and their precursor lesions. A histologic and inmunohistochemical study of 23 cases. Cancer 1991; 67: 663-672.

(14) RINDI G, LUINETTI O, CORNAGGIA M, CAPELLA C, SOLCIA E. Three subtypes of Gastric Argyrophill Carcinoid and the Gastric Neuroendocrine Carcinoma: A Clinicopathology study. Gastroenterol 1993; 104: 994-1006.

(15) CARISON HE, LOWITZ BB, CASCIATO DD. Tumores Endócrinos. En Manual de Oncología Clínica, 2da. Edición. Salvat 1990, p. 278-283.

(16) COTRAN RS, KUMAR V, ROBBINS SL. Robbins Pathology Basis of Disease. Philadelphia, WB Sanders, 1989.

(17) AJANI JA, CARRASCO H, SAMAAN NA. Therapeutic options in patients with advanced islet cell and carcinoids tumors. Reg Cancer Treat 1991; 3: 235-242.

(18) MOERTEL CG. Treatment of Carcinoids Tumors and the malignant Carcinoid Syndrome. J Clin Oncol 1983; 1: 727-740.

(19) LAMBERTS SW, BAKKER WH, REUBI JC. Somastotatin receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 23: 1246- 1249.

(20) NORTON JA, DOPPMANN JL, VENSEN RT. Curative resection in Zollinger-Ellison Syndrome: Results of a 10 years prospective study. Ann Surg 1992; 215: 8-18.

(21) LEGHA SS, VALDIVIESO M, NELSON RS. Chemotherapy for metastatic carcinoids tumors with Interferon not as suggested ?. Cancer 1991; 67: 547-549.

(22) MOERTEL CG, KVOLS LK, O’CONNELL MJ. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasm. Cancer 1991; 68: 227-232.

(23) KVOLS LK, MOERTEL CG, O’CONNELL MJ. Treatment of the malignant carcinoid syndrome: Evaluation of a long acting somastotatin analogue. N Engl J Med 1986; 315: 663-666.

(24) WYNICH D, BLOOM SR. Clinical Review: The use of the long acting somastotatin analog Octreatide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991; 73: 1-3.

(25) REUBI JC, KOALS LK, WASER B. Detection of somastotatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5972.

(26) OBERG K, FUNA K, ALM G. Effects of Leucocyte interferon on clinical symtoms and hormonal levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983; 309: 129- 133.

(27) VALIRNAK M, JARVINEN H, SALMELLA P. Is the treatment of metastatic carcinoid tumor with interferon not as suggested?. Cancer 1991; 67:547-591.